Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Alpha has not published a narrative summary because the current public source set is not sufficient.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Connections

Explore the roles, education and affiliations published in this record.

Mereo BioPharma Group plc

Open Mereo BioPharma Group plc profile →

Director at Mereo BioPharma Group plc

2019-01-01 → End not stated

current · source reported

Observed: 2026-09-13

Mereo BioPharma Gr…Mereo BioPharma Group plcTvardi Therapeutic…Tvardi Therapeutics, Inc.X4 Pharmaceuticals…X4 Pharmaceuticals, IncMichael S. Wyzga

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingTVRD DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 2 · Sec FilingMREO DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingXFOR DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:michael-s-wyzga
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Mereo BioPharma Group plc1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Lead Independent Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit and Risk, Nomination and Corporate Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at MSW Consulting Inc.1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: President1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  2. https://www.sec.gov/Archives/edgar/data/1346830/000110465926047695/tvrd-20260609xdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at Tvardi Therapeutics, Inc. (NASDAQ: TVRD)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  4. https://www.sec.gov/Archives/edgar/data/1719714/000119312526148832/mreo-20260407.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Mereo BioPharma Group plc (NASDAQ: MREO) · Board membership

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  6. https://www.sec.gov/Archives/edgar/data/1501697/000150169726000031/xfor-20260320.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at X4 Pharmaceuticals, Inc (NASDAQ: XFOR)